{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:11:21Z","timestamp":1774678281249,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Katholisches Klinikum Bochum gGmbh"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Ofatumumab (Kesimpta<jats:sup>\u00ae<\/jats:sup>) is a subcutaneous CD20-targeting antibody approved in Germany in 2021 for the treatment of relapsing multiple sclerosis (RMS). After careful instruction, patients can administer the treatment themselves. We previously reported data of 101 patients (Klimas et al. in Nervenarzt 94:923\u2013933, 2023). The objective of this longitudinal study is to explore the tolerability and acceptability of ofatumumab from a patient perspective over a follow up period of 6\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this prospective observational real-world study, we report follow up data of 81 patients. We evaluated sociodemographic data, disease duration, duration and side effects of ofatumumab use, expanded disability status scale (EDSS), Beck Depression Inventory II (BDI-II), Short-Form 36 (SF-36), Fatigue Scale of Motor and Cognitive Functions (FSMC), and modified Multiple Sclerosis Functional Composite Test (MSFC). In addition, we asked for subjective treatment outcomes, such as impact on quality of life, walking distance, concentration, mood, medication adherence, fatigue and the subjective course of MS on a numerical rating scale (1\u2009=\u2009very negative; 5\u2009=\u2009very positive). Furthermore, treatment discontinuations were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The average duration of ofatumumab treatment was 10\u00a0months. In comparison to previous published data of our cohort, patients reported a significant increase in headache (10% up to 26%, p\u2009=\u20090.004) and limb pain (5% up to 26%, p\u2009&lt;\u20090.001) as persistent side effects after the injections. More patients reported a very positive effect (p\u2009&lt;\u20090.0001) on quality of life. 4 confirmed  relapses occurred but no EDSS worsening, and no treatment discontinuations were documented during the observation period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>As previously described, our prospective study indicates that patients have a good tolerability of ofatumumab, precisely because of the mild and few side effects at the first administration. However, the longer the observation period, the more headaches and limb pain occurred after the injections. Despite this, patients\u2019 subjective quality of life improved. There were no discontinuations during the follow-up period, with the limitation of a high loss to follow-up.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12581-0","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T22:01:47Z","timestamp":1721685707000},"page":"6080-6088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Quality of life and tolerability of B-cell directed therapy of multiple sclerosis with ofatumumab in a patient-centered real-world observational study"],"prefix":"10.1007","volume":"271","author":[{"given":"Anna-Sophia","family":"Karl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5989-2195","authenticated-orcid":false,"given":"Rafael","family":"Klimas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melina","family":"Katsimpoura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Sgodzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Theile-Ochel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip Lennart","family":"Poser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Gisevius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Faissner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Salmen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Nastos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremias","family":"Motte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"12581_CR1","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, Ocampo A, Hatami F, \u010cuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147\u20133161","journal-title":"Brain"},{"key":"12581_CR2","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1177\/1352458516675039","volume":"23","author":"A Kavaliunas","year":"2017","unstructured":"Kavaliunas A, Manouchehrinia A, Stawiarz L, Ramanujam R, Agholme J, Hedstr\u00f6m AK, Beiki O, Glaser A, Hillert J (2017) Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 23:1233\u20131240","journal-title":"Mult Scler"},{"key":"12581_CR3","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1111\/ene.13692","volume":"25","author":"TA Chalmer","year":"2018","unstructured":"Chalmer TA, Baggesen LM, N\u00f8rgaard M, Koch-Henriksen N, Magyari M, Sorensen PS (2018) Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 25:1262-e110","journal-title":"Eur J Neurol"},{"key":"12581_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL, Zhovits Ryerson L, Kister I, Malpas CB, Sharmin S, Horakova D, Kubala Havrdova E, Spelman T, Izquierdo G, Eichau S et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19:307\u2013316","journal-title":"Lancet Neurol"},{"key":"12581_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00415-023-12007-3","volume":"271","author":"SR Delgado","year":"2024","unstructured":"Delgado SR, Faissner S, Linker RA, Rammohan K (2024) Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment. J Neurol 271:1515\u20131535","journal-title":"J Neurol"},{"key":"12581_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Rammohan KW et al (2017) Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 376:209\u2013220","journal-title":"N Engl J Med"},{"key":"12581_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676\u2013688","journal-title":"N Engl J Med"},{"key":"12581_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","volume":"18","author":"S Faissner","year":"2019","unstructured":"Faissner S, Plemel JR, Gold R, Yong VW (2019) Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov 18:905\u2013922","journal-title":"Nat Rev Drug Discov"},{"key":"12581_CR9","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1177\/13524585211044479","volume":"28","author":"A Bar-Or","year":"2022","unstructured":"Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G et al (2022) Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler 28:910\u2013924","journal-title":"Mult Scler"},{"key":"12581_CR10","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","volume":"78","author":"T Spelman","year":"2021","unstructured":"Spelman T, Magyari M, Piehl F, Svenningsson A, Rasmussen PV, Kant M, Sellebjerg F, Joensen H, Hillert J, Lycke J (2021) Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis: data from 2 different national strategies. JAMA Neurol 78:1197\u20131204","journal-title":"JAMA Neurol"},{"key":"12581_CR11","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H et al (2020) Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med 383:546\u2013557","journal-title":"N Engl J Med"},{"key":"12581_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00115-023-01470-y","volume":"94","author":"R Klimas","year":"2023","unstructured":"Klimas R, Karl A-S, Poser PL, Sgodzai M, Theile-Ochel S, Gisevius B, Faissner S, Nastos I, Gold R, Motte J (2023) Over one year of B-cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study. Nervenarzt 94:923\u2013933","journal-title":"Nervenarzt"},{"key":"12581_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s00103-004-0933-1","volume":"47","author":"U Ellert","year":"2004","unstructured":"Ellert U, Kurth B-M (2004) Methodische Betrachtungen zu den Summenscores des SF-36 anhand der erwachsenen bundesdeutschen Bev\u00f6lkerung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:1027\u20131032","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"12581_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001744","volume":"11","author":"KGM Moons","year":"2014","unstructured":"Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, Reitsma JB, Collins GS (2014) Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med 11:e1001744","journal-title":"PLoS Med"},{"key":"12581_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS et al (2017) Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 376:221\u2013234","journal-title":"N Engl J Med"},{"key":"12581_CR16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1207\/S15324796ABM2302_7","volume":"23","author":"DC Mohr","year":"2001","unstructured":"Mohr DC, Boudewyn AC, Likosky W, Levine E, Goodkin DE (2001) Injectable medication for the treatment of multiple sclerosis: the influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 23:125\u2013132","journal-title":"Ann Behav Med"},{"key":"12581_CR17","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0175","volume":"12","author":"V Bhan","year":"2023","unstructured":"Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, Adlard N, Vudumula U, Gudala K, Dutta N, Grima D, Mouallif S et al (2023) Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. J Comp Eff Res 12:e220175","journal-title":"J Comp Eff Res"},{"key":"12581_CR18","doi-asserted-by":"publisher","first-page":"175628642412413","DOI":"10.1177\/17562864241241382","volume":"17","author":"R Gold","year":"2024","unstructured":"Gold R, Schmidt S, Deisenhammer F, Motte J, Richter N, Taipale K, Salmen HC, Bohland C, Schirduan K (2024) Real-world evidence and patient preference for subcutaneous versus intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study. Ther Adv Neurol Disord 17:17562864241241382","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12581-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12581-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:23:03Z","timestamp":1725538983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12581-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12581"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12581-0","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"27 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anna-Sophia Karl: none. Rafael Klimas: received travel support from Takeda, Grifols, Ruhr-University Bochum and research support by Ruhr-University Bochum, and LFB Group France; none related to this manuscript. Melina Katsimpoura: none. Philip Lennart Poser: none. Simon Theile-Ochel: none. Melissa Sgodzai: none. Barbara Gisevius: none. Simon Faissner: has received speaker\u2019s and\/or scientific board honoraria and\/or congress travel support from Academy2, AstraZeneca, Biogen, BMS, Celgene, Genesis Pharma, Hexal, Janssen, Merck, Neuraxpharm, Novartis and Roche and grant support from Ruhr-University Bochum, German Research Foundation (DFG), DMSG, DMSG North-Rhine-Westfalia, Stiftung f\u00fcr therapeutische Forschung, Lead Discovery Center GmbH and Novartis; none related to this manuscript. Anke Salmen: received speaker honoraria for activities with Bristol Myers Squibb, CSL Behring, Novartis, and Roche, and research support by the Baasch Medicus Foundation, the Medical Faculty of the University of Bern, the Swiss MS Society and the regional association of North Rhine-Westphalia of the German MS Society (DMSG Landesverband NRW). Ralf Gold: serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, and Novartis; has received speaker honoraria from Biogen Idec, Teva Pharmaceutical Industries Ltd., Bayer Schering Pharma, and Novartis; serves as editor for Therapeutic Advances in Neurological Diseases and on the editorial boards of Experimental Neurology and the Journal of Neuroimmunology; and receives research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer Schering Pharma, Genzyme, Merck Serono, and Novartis, none related to this manuscript. Jeremias Motte: received speaker honoraria for activities with Alnylam, Biogen Idec, travel grants from Biogen Idec, Novartis AG, Teva, and Eisai GmbH; and his research is supported by Biogen Idec, Novartis AG, Kyverna Therapeutics Inc., GBS\/CIDP Foundation International, Klaus TschiraFoundation, Hertie Foundation and Ruhr-University, Bochum, regional association of North Rhine-Westphalia of the German MS Society (DMSG Landesverband NRW); none related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki of 1975 and approved by the local ethics committee of the Ruhr University Bochum (20-6827).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}